Selexis SA and SpyBiotech have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV)
BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...